Jan Wahlström

CEO

Jan Wahlström

Born in 1967
CEO since 2025

Education:
Chemistry studies at Uppsala University, DIHM business degree marketing and finance

Other important offices:
Board memeber Arcoma AB (publ)

Previous positions:
CEO Mabtech, CEO Elos Medtech, CEO Biolin Scientific

Holdings in the company: -

 

 

 

Sabina Berlin

CFO

Sabina Berlin

Born in 1983
CFO since 2021

Education:
M.Sc. in Business and Economics, Gothenburg School of Business.

Other important offices:
Director of Zymology AB.

Previous positions:
CEO of Juno Ekonomi AB, CFO of IRRAS AB.

Holdings in the company:
Number of shares: 5,942
Employee stock options (Program 2023/2027): 20,000
Employee stock options (Program 2024/2028): 25,000

Theis Kipling

CCO

Theis Kipling

Born in 1982
CCO since 2022

Education:
Master's degree in Business Administration, Copenhagen Business School.

Other important offices: -

Previous positions:
CCO of Atlas Antibodies, international management positions in marketing/sales at Agilent, Global Brand Management at Lundbeck A/S.

Holdings in the company:
Number of shares: 20,809
Employee stock options (Program 2022/2025): 60,000
Employee stock options (Program 2023/2027): 20,000
Employee stock options (Program 2024/2028): 7,500

Camilla Wiberg

CHRO

Camilla Wiberg

Born 1979
CHRO since 2022

Education:
Master's degree in Human Resources Management, Linköping University.

Other important offices: -

Previous positions:
Interim HR Consultant and HR Manager at Orkla Care AB and Avanade Sweden AB.

Holdings in the company:
Number of shares: 200
Employee stock options (Program 2022/2025): 40,000
Employee stock options (Program 2023/2027): 10,000
Employee stock options (Program 2024/2028): 1 000

Michael Uhlin

CSO

Michael Uhlin

Born 1978
CSO since 2023

Education:
Masters in Biomedicine, Karolinska Institutet, Stockholm. PhD in Infection biology, Karolinska Institutet. Postdoctoral studies at Karolinska University hospital in Transplantation Immunology. 

Other important offices: 
Adjunct Professor in Clinical Immunology at Karolinska Institutet.

Previous positions:
CSO in XNK Therapeutics. Head of Clinical Immunology at Karolinska University Hospital. Head of Development and IT at Karolinska University Hospital. Head of division Therapeutic Immunology and Transfusion Medicine at Karolinska Institutet. Head of Research at Karolinska University Hospital.   

Holdings in the company:
Number of shares:  200
Employee stock options (Program 2023/2027): 40,000
Employee stock options (Program 2024/2028): 5,000

Robin Sortebech

VP Supply Chain

Robin Sortebech

Born in 1970
VP Supply Chain since 2025

Education:
Social Sciences, St. Olov Sarpsborg.

Other important offices: -

Previous positions:
Manufacturing Director at Cepheid AB.

Holdings in the company:
Number of shares: 200

Olle Myrberg

VP Quality & Regulatory Affairs

Olle Myrberg

Born in 1978
VP Quality & Regulatory Affairs since 2018

Education:
M.Sc. Chemical/ Pharmaceutical Engineering, Uppsala University. Executive Leadership Program, SSE Executive Education.

Other important offices: -

Previous positions:
Head of Regulatory Unit at Cepheid, SME at GE Healthcare, Medical Product Investigator at the Swedish Medical Products Agency.

Holdings in the company:
Number of shares: 18,739, options for a total of 12,000 Company shares.
Employee stock options (Program 2024/2028): 12 000